Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism

被引:24
作者
Doebele, RC
Pashine, A
Liu, W
Zaller, DM
Belmares, M
Busch, R
Mellins, ED
机构
[1] Stanford Univ, Dept Pediat, Sch Med, Ctr Clin Sci Res,Div Immunol & Transplantat Biol, Stanford, CA 94305 USA
[2] Merck & Co Inc, Res Labs, Rahway, NJ 07065 USA
[3] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
关键词
D O I
10.4049/jimmunol.170.9.4683
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
During maturation of MHC II molecules, newly synthesized and assembled complexes of MHC II alphabeta dimers with invariant chain (Ii) are targeted to endosomes, where Ii is proteolyzed, leaving remnant class II-associated Ii peptides (CLIP) in the MHC II peptide binding groove. CLIP must be released, usually with assistance from the endosomal MHC II peptide exchange factor, HLA-DM, before MHC II molecules can bind endosomal peptides. Structural factors that control rates of CLIP release remain poorly understood, although peptide side chain-MHC II specificity pocket interactions and MHC II polymorphism are important. Here we report that mutations betaS11F, betaS13Y, betaQ70R, betaK71E, betaK71N, and betaR74Q, which map to the P4 and P6 pockets of the groove of HLA-DR3 molecules, as well as alphaG20E adjacent to the groove, are associated with elevated CLIP in cells. Most of these mutations increase the resistance of CLIP-DR3 complexes to dissociation by SDS. In vitro, the groove mutations increase the stability of CLIP-DR3 complexes to dissociation. Dissociation rates in the presence of DM, as well as coimmunoprecipitation of some mutant DR3 molecules with DM, are also diminished. The profound phenotypes associated with some of these point mutations suggest that the need to maintain efficient CLIP release represents a constraint on naturally occurring MHC II polymorphism.
引用
收藏
页码:4683 / 4692
页数:10
相关论文
共 61 条
[1]   IN-VIVO AND IN-VITRO FORMATION AND DISSOCIATION OF HLA-DR COMPLEXES WITH INVARIANT CHAIN-DERIVED PEPTIDES [J].
AVVA, RR ;
CRESSWELL, P .
IMMUNITY, 1994, 1 (09) :763-774
[2]   Structural factors contributing to DM susceptibility of MHC class II/Peptide complexes [J].
Belmares, MP ;
Busch, R ;
Wucherpfennig, KW ;
McConnell, HM ;
Mellins, ED .
JOURNAL OF IMMUNOLOGY, 2002, 169 (09) :5109-5117
[3]   Relaxed DM requirements during class II peptide loading and CD4+ T cell maturation in BALB/c mice [J].
Bikoff, EK ;
Wutz, G ;
Kenty, GA ;
Koonce, CH ;
Robertson, EJ .
JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :5087-5098
[4]   Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes [J].
Bischof, F ;
Wienhold, W ;
Wirblich, C ;
Malcherek, G ;
Zevering, O ;
Kruisbeek, AM ;
Melms, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (21) :12168-12173
[5]   Accessory molecules for MHC class II peptide loading [J].
Busch, R ;
Doebele, RC ;
Patil, NS ;
Pashine, A ;
Mellins, ED .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (01) :99-106
[6]  
Busch R, 1998, J IMMUNOL, V160, P734
[7]   Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM [J].
Busch, R ;
Reich, Z ;
Zaller, DM ;
Sloan, V ;
Mellins, ED .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (42) :27557-27564
[8]   PREDOMINANT NATURALLY PROCESSED PEPTIDES BOUND TO HLA-DR1 ARE DERIVED FROM MHC-RELATED MOLECULES AND ARE HETEROGENEOUS IN SIZE [J].
CHICZ, RM ;
URBAN, RG ;
LANE, WS ;
GORGA, JC ;
STERN, LJ ;
VIGNALI, DAA ;
STROMINGER, JL .
NATURE, 1992, 358 (6389) :764-768
[9]  
CLARK EA, 1984, LEUKOCYTE TYPING
[10]  
COTNER T, 1989, J BIOL CHEM, V264, P11107